Bristol Myers Squibb (BMY-N) Stock Predictions - Stockchase
WATCH LIST
144
Bristol Myers Squibb (BMY-N)

ON STOCKCHASE SINCE Apr 2001

biotechnology/pharmaceutical

Bristol Myers Squibb

BMY-N

30 watching          
Join the Discussion

Bristol Myers Squibb (BMY-N) SAVE Apr, 19, 2019, 8:05 am

45.52 0.28 (0.61%)

About Bristol Myers Squibb (BMY-N)

Bristol-Myers Squibb is an American pharmaceutical company, headquartered in New York City. Bristol-Myers Squibb manufactures prescription pharmaceuticals in several therapeutic areas, including cancer, ... More at Wikipedia

What the experts are saying about BMY-N



  • All
  • Filtered
Signal Opinion Expert
HOLD
Some people don’t like the deal. CELG-Q and BMY-N like the deal. Stakeholders have come out against it. There is a lot of spread which represents the risk. Stay with it but understand the risks and don't have too big an exposure to it as there is deal risk.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Some people don’t like the deal. CELG-Q and BMY-N like the deal. Stakeholders have come out against it. There is a lot of spread which represents the risk. Stay with it but understand the risks and don't have too big an exposure to it as there is deal risk.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Gordon Reid

President, GoodReid Investment ...

Price Price
$48.920
Owned Owned
Unknown

HOLD
Bristol Myers Squibb(BMY-N) 

December 17, 2018

He bought a put as this stock went down. Healthcare has been under pressure lately. Maybe have a January expiration. It's a sort of defensive stock, so okay to hold onto going into 2019.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
He bought a put as this stock went down. Healthcare has been under pressure lately. Maybe have a January expiration. It's a sort of defensive stock, so okay to hold onto going into 2019.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Richard Croft

President, R.N. Croft Financial...

Price Price
$50.920
Owned Owned
Unknown

BUY
Bristol Myers Squibb(BMY-N) 

December 3, 2018

40% of their 2020 revenue is coming from Own diversity and own a few of these companies.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
40% of their 2020 revenue is coming from Own diversity and own a few of these companies.
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Paul Macdonald

Chief Inve, Harvest Portfolios G...

Price Price
$53.280
Owned Owned
Yes

TOP PICK
Bristol Myers Squibb(BMY-N) 

November 22, 2018

They have a good, innovative pipeline. If you can get it in the low $50s, it will be a $60 stock next year. This is a good entry point. He likes it here below multiple multiples. (Analysts’ price target is $59.23)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
They have a good, innovative pipeline. If you can get it in the low $50s, it will be a $60 stock next year. This is a good entry point. He likes it here below multiple multiples. (Analysts’ price target is $59.23)
biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$0.000
Owned Owned
Yes

PAST TOP PICK

(A Top Pick Aug 10/17, Down 1%)  It went back down to where he recommended it.  He still really likes the company.  They were put back into second place so the stock came down.  He thinks investors should consider buy it again.  It was almost a Top Pick.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Aug 10/17, Down 1%)  It went back down to where he recommended it.  He still really likes the company.  They were put back into second place so the stock came down.  He thinks investors should consider buy it again.  It was almost a Top Pick.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$54.670
Owned Owned
Yes

WATCH

 The healthcare sector tends to be known as a defensive sector, because of the stability of earnings.  The issue this year was that President Trump threatened to come after the pharma sector for medication costs.  Seasonally the sector tends to do best from August into October.  He would wait on this for a short term test of support $47 and this could be the level to get into.   (Analysts’ price target is $59 )

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

 The healthcare sector tends to be known as a defensive sector, because of the stability of earnings.  The issue this year was that President Trump threatened to come after the pharma sector for medication costs.  Seasonally the sector tends to do best from August into October.  He would wait on this for a short term test of support $47 and this could be the level to get into.   (Analysts’ price target is $59 )

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Brooke Thackray

Research A, Horizons ETFs (Canad...

Price Price
$52.500
Owned Owned
No

DON'T BUY

It is consolidating here. He suspects that the announcements from the trump Administration on American Patients First affected it. Pharmaceutical companies in general are being affected. Not looking too favorable on a technical basis.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

It is consolidating here. He suspects that the announcements from the trump Administration on American Patients First affected it. Pharmaceutical companies in general are being affected. Not looking too favorable on a technical basis.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Jon Vialoux

Research A, CastleMoore Inc....

Price Price
$52.710
Owned Owned
No

DON'T BUY

The whole pharma sector is suffering with pricing pressures.  They have issues with a new drug they have come out with.  He would stay away.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

The whole pharma sector is suffering with pricing pressures.  They have issues with a new drug they have come out with.  He would stay away.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$51.320
Owned Owned
No

PAST TOP PICK

(A Top Pick Feb 8/17, Down 1%)  You should have taken profits on the way up.  The major market for cancer is lung, with the most profit.  These guys are one of two leaders in this industry, neck and neck with MRK-N, the other player.  There were whispers of other companies possibly taking BMY-N out.  He still likes it and encourages investors to buy a bit of it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Feb 8/17, Down 1%)  You should have taken profits on the way up.  The major market for cancer is lung, with the most profit.  These guys are one of two leaders in this industry, neck and neck with MRK-N, the other player.  There were whispers of other companies possibly taking BMY-N out.  He still likes it and encourages investors to buy a bit of it.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$51.450
Owned Owned
Yes

DON'T BUY

They did a great job bringing on oncology products to fight cancer, but beyond oncology he's not excited about Bristol. There are better companies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They did a great job bringing on oncology products to fight cancer, but beyond oncology he's not excited about Bristol. There are better companies.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Ashley Misquitt

Senior Po, Empire Life ...

Price Price
$52.380
Owned Owned
Unknown

DON'T BUY

They have a few cancer drugs out of the pipeline that are growing. That said, their shares aren't cheap enough to step in. The problem is if the FDA decides to change their labelling that would turn a $5-billion drug into a $1-billion one. The dividend is secure.  While all these companies are making money, the struggle lies in earnings growth.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

They have a few cancer drugs out of the pipeline that are growing. That said, their shares aren't cheap enough to step in. The problem is if the FDA decides to change their labelling that would turn a $5-billion drug into a $1-billion one. The dividend is secure.  While all these companies are making money, the struggle lies in earnings growth.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Lorne Steinberg

President , Lorne Steinberg Weal...

Price Price
$60.480
Owned Owned
Unknown

PAST TOP PICK
Bristol Myers Squibb(BMY-N) 

January 10, 2018

(A Top Pick Nov 1/16. Up 26%.) Still a top holding across all his funds. Likes its innovative pipeline of drugs, especially its immuno ecology for fighting cancer. Thinks it has the strongest portfolio out there. Because of their strong pipeline, this would be an M&A target. Repatriation of cash by a lot of majors will spur M&A in healthcare.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Nov 1/16. Up 26%.) Still a top holding across all his funds. Likes its innovative pipeline of drugs, especially its immuno ecology for fighting cancer. Thinks it has the strongest portfolio out there. Because of their strong pipeline, this would be an M&A target. Repatriation of cash by a lot of majors will spur M&A in healthcare.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$62.010
Owned Owned
Yes

BUY
Bristol Myers Squibb(BMY-N) 

January 2, 2018

One of the few stocks that has actually traded up and down in some kind of range. Volumes have been pretty steady. We are a long way from the top, but the chart shows some kind of support level being built in the low $60s. This is a stock he would own. It looks good here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

One of the few stocks that has actually traded up and down in some kind of range. Volumes have been pretty steady. We are a long way from the top, but the chart shows some kind of support level being built in the low $60s. This is a stock he would own. It looks good here.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Elliott Fishman

Director o, Trading Services Gro...

Price Price
$61.310
Owned Owned
Unknown

PAST TOP PICK
Bristol Myers Squibb(BMY-N) 

October 31, 2017

(A Top Pick Feb 8/17. Up 20%.) Still his favourite Pharma name. Had a small one-cell lung cancer solution, and the market is starting to get its head around that they are still in the game. We should get results in the 1st half of 2018. Over the next 5-6 years, their pipeline of drugs is so vast and undervalued, that as drugs come through fruition into cash flow and get approval, there are more and more tailwinds. It could be a potential take out candidate.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(A Top Pick Feb 8/17. Up 20%.) Still his favourite Pharma name. Had a small one-cell lung cancer solution, and the market is starting to get its head around that they are still in the game. We should get results in the 1st half of 2018. Over the next 5-6 years, their pipeline of drugs is so vast and undervalued, that as drugs come through fruition into cash flow and get approval, there are more and more tailwinds. It could be a potential take out candidate.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
Robert Lauzon

Deputy Chi, Middlefield Capital ...

Price Price
$61.660
Owned Owned
Yes

COMMENT
Bristol Myers Squibb(BMY-N) 

October 4, 2017

(Market Call Minute.) This has a lung cancer drug that is starting to face competition. With this, you will have to be either patient or cautious.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments

(Market Call Minute.) This has a lung cancer drug that is starting to face competition. With this, you will have to be either patient or cautious.

biotechnology/pharmaceutical
0 0 0 0 0
0 comments
David Driscoll

President , Liberty Internationa...

Price Price
$64.740
Owned Owned
No

Showing 1 to 15 of 144 entries
Successfully Saved Company
Successfully Saved Company
4+
JOIN THE DISCUSSION
4 comments in the last 7 days